Profile data is unavailable for this security.
About the company
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company operates through the Pharmaceutical products, including ingredients and intermediaries segment. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its General category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, among others. The Company has a manufacturing plant at Baddi, Himachal Pradesh. It manufactures and markets pharmaceuticals nationally and internationally to various regulated markets.
- Revenue in INR (TTM)817.15m
- Net income in INR-175.35m
- Incorporated2002
- Employees293.00
- LocationBrooks Laboratories Ltd502 Andheri, Andheri Kurla RoadMUMBAI 400093IndiaIND
- Phone+91 2 261933100
- Fax+91 2 261933114
- Websitehttps://www.brookslabs.net/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Par Drugs and Chemicals Ltd | 1.04bn | 182.71m | 3.63bn | 122.00 | 19.84 | 3.75 | 16.60 | 3.48 | 14.86 | 14.86 | 84.62 | 78.64 | 0.9851 | 7.61 | 5.20 | 8,531,213.00 | 17.29 | 13.52 | 20.01 | 16.46 | 66.70 | 43.71 | 17.55 | 13.42 | 2.87 | 205.06 | 0.00 | -- | -0.1132 | 15.60 | 27.94 | 42.01 | 77.72 | -- |
| Brooks Laboratories Ltd | 817.15m | -175.35m | 3.65bn | 293.00 | -- | -- | -- | 4.47 | -6.84 | -6.84 | 31.86 | -- | -- | -- | -- | 2,788,911.00 | -- | -13.86 | -- | -22.90 | 29.09 | 26.19 | -21.46 | -27.47 | -- | 0.0861 | -- | -- | 25.76 | 7.63 | 6.26 | -- | -12.73 | -- |
| SMS Lifesciences India Ltd | 3.24bn | 178.73m | 4.15bn | 574.00 | 23.25 | -- | 12.91 | 1.28 | 59.10 | 59.10 | 1,070.58 | -- | -- | -- | -- | 5,642,058.00 | -- | 4.08 | -- | 6.73 | 34.82 | 29.68 | 5.33 | 4.46 | -- | 2.88 | -- | 2.61 | -3.04 | -4.13 | -20.68 | -12.62 | -3.09 | 0.00 |
| Venus Remedies Ltd. | 6.15bn | 221.01m | 4.16bn | 1.19k | 18.81 | 0.8424 | 8.87 | 0.6772 | 16.56 | 16.56 | 461.13 | 369.72 | 0.945 | 2.68 | 8.72 | 5,178,093.00 | 3.40 | 4.82 | 4.06 | 6.17 | 39.06 | 38.90 | 3.60 | 5.58 | 2.69 | 1,660.39 | 0.0765 | -- | 8.27 | 13.32 | 7.25 | -- | 6.38 | -- |
| Holder | Shares | % Held |
|---|---|---|
| quant Money Managers Ltd.as of 30 Sep 2024 | 1.01m | 3.86% |
